相关实验视频

Updated: Jun 4, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

在治疗多发性骨髓瘤方面,基于反感性寡核酸的方法

Madalina Oprea¹, Mariana Ionita²

¹Faculty of Medical Engineering, National University of Science and Technology Politehnica Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; Advanced Polymer Materials Group, National University of Science and Technology Politehnica Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania.

International journal of biological macromolecules

|December 28, 2024

概括

反感性寡核酸 (ASOs) 提供了一个有希望的,个性化的方法来治疗多发性骨髓瘤 (MM) 通过沉默关键基因. 虽然临床试验显示出潜力,但在FDA批准之前,需要进一步研究以解决毒性和财务问题.

科学领域:

血液学的恶性瘤
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

多发性骨髓瘤 (MM) 是一种正在上升的血液性恶性瘤,预后不佳,往往对现有治疗变得耐药.
目前对MM的治疗方法,包括蛋白酶体抑制剂和干细胞移植,都有局限性.
反感性寡核酸 (ASO) 是一种新的治疗策略,针对涉及MM的特定基因.

研究的目的:

为治疗多发性骨髓瘤 (MM) 提供基于反感性寡核酸 (ASO) 的治疗方法的全面审查.
分析MM治疗中ASO的机制,化学修饰,传递系统和遗传点.
讨论MM中ASO治疗的当前挑战和未来前景.

主要方法:

对针对MM的Bcl-2,Mcl-1,STAT3和IRF4等基因的ASO进行临床前和临床研究的审查.
分析ASO介导的基因沉默机制,包括RNA裂变和阻塞.
检查潜在的ASO传递系统和化学修改.

主要成果:

临床前和临床研究表明,针对MM的特定基因的ASO取得了有希望的结果.
ASO已经显示出对瘤细胞增殖和生存至关重要的基因沉默的潜力.
几种ASO配方已经进入临床试验,表明治疗潜力.

结论:

基于ASO的疗法作为多发性骨髓瘤的个性化治疗具有显著的前景.
需要进一步的研究来解决与长期毒性,伦理和金融问题相关的挑战,以便获得FDA的批准.
对ASO输送系统和化学修饰的持续研究将对推进这种治疗方法至关重要.

关键词:

有控制的交付方式.在DNA纳米结构中.基因治疗是一种基因疗法.

更多相关视频

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...